Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 1—January 2008
THEME ISSUE
International Polar Year
Research

International Circumpolar Surveillance System for Invasive Pneumococcal Disease, 1999–2005

Michael G. Bruce*Comments to Author , Shelley L. Deeks†1, Tammy Zulz*, Dana Bruden*, Christine Navarro†, Marguerite Lovgren‡, Louise Jette§, Karl G. Kristinsson¶, Gudrun Sigmundsdottir¶, Knud Brinkløv Jensen#, Oistein Lovoll**, J. Pekka Nuorti††, Elja Herva‡‡, Anders Nystedt§§, Anders Sjostedt¶¶, Anders Koch##, Thomas W. Hennessy*, Alan J. Parkinson*, and the International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group
Author affiliations: *Centers for Disease Control and Prevention, Anchorage, Alaska, USA; †Public Health Agency of Canada, Ottawa, Ontario, Canada; ‡National Centre for Streptococcus, Edmonton, Alberta, Canada; §Quebec Public Health Laboratory, Ste. Anne-de-Bellevue, Quebec, Canada; ¶Landspitali University Hospital, Reykjavik, Iceland; #Institution of the Chief Medical Officer, Nuuk, Greenland; **Norwegian Institute of Public Health, Oslo, Norway; ††National Public Health Institute, Helsinki, Finland; ‡‡National Public Health Institute, Oulu, Finland; §§Sunderby Hospital, Lulea, Sweden; ¶¶Umea University, Umea, Sweden; ##Statens Serum Institut, Copenhagen, Denmark;

Main Article

Table 5

Most prevalent serotypes in 6 countries reporting Streptococcus pneumoniae type to ICS and proportion of isolates covered by PCV7 and PCV13 vaccines*

RankAlaska
Canada
Greenland, 
n = 60Iceland, 
n = 269Norway, 
n = 291Finland, 
n = 3,947
Pre-PCV7, 1999–2000, 
n = 224Post-PCV7, 2001–2005, 
n = 453Pre-PCV7, 
1999–2002, 
n = 158Post-PCV7, 
2003–2005, 
n = 82
114 (17%)19A (11%)1 (34%)1 (24%)1 (22%)7 (20%)4, 14 (18%)14, 4 (12%)
24, 7F (9%)4 (8%)14 (11%)8 (11%)12F (15%)14 (12%)9 (11%)9V (8%)
39V (8%)12F (8%)4 (9%)3 (7%)4 (12%)23 (12%)6 (9%)3, 23F, 7F (7%)
419F (6%)3, 7F, 8 (7%)8 (8%)10A, 18C, 22F (6%)22F (8%)19 (10%)23 (8%)6B (6%)
5
6B (6%)
14 (6%)

6B, 9V (6%)
6B (5%)
3 (7%)
9 (10%)
7 (7%)
19A, 19F (4%)
Proportion of serotyped isolates covered by PCV7 and PCV13 vaccines (<2 y of age)
PCV782% (51/62)21% (16/77)76% (25/33)21% (3/14)50% (3/6)51% (23/45)37% (10/27)NA
PCV1392% (57/62)57% (44/77)94% (31/33)43% (6/14)83% (5/6)60% (27/45)56% (15/27)NA

*ICS, International Circumpolar Surveillance; PCV7, 7-valent pneumococcal conjugate vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F); PCV13, 13-valent pneumococcal conjugate vaccine (7 PCV7sero types plus 1, 3, 5, 6A, 7F, and 19A); NA, not available.

Main Article

1Current affiliation: National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia

2The International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group: Jean-François Proulx (Department of Public Health, Nunavik Regional Board of Health and Social Services, Quebec City, Quebec, Canada); Robert Carlin (Department of Public Health, Cree Board of Health and Social Services of James Bay, Montreal, Quebec, Canada); Andre Corriveau, Cheryl Case (Northwest Territory Department of Health and Social Services, Yellowknife, Northwest Territories, Canada); Bryce Larke, Colleen Hemsley (Yukon Health and Social Services, Whitehorse, Yukon, Canada); Isaac Sobel, Carolina Palacios (Nunavut Department of Health, Iqaluit, Nunavut, Canada); Gregory Tyrell, Marguerite Lovgren (National Centre for Streptococcus, Edmonton, Alberta, Canada); Alisa Reasonover, Michael G. Bruce, Tammy Zulz, Dana Bruden, Thomas W. Hennessy, Alan J. Parkinson (Centers for Disease Control and Prevention, Anchorage, Alaska, USA); Shelley L. Deeks (National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia); Christine Navarro (Public Health Agency of Canada, Ottawa, Ontario, Canada); Louise Jette (Quebec Public Health Laboratory, Ste. Anne-de-Bellevue, Quebec, Canada); Karl Kristinsson, Gudrun Sigmundsdottir (Landspitali University Hospital, Reykjavik, Iceland); Knud Brinkløv Jensen (Institution of the Chief Medical Officer, Nuuk, Greenland); Oistein Lovoll (Norwegian Institute of Public Health, Oslo, Norway); J. Pekka Nuorti (National Public Health Institute, Helsinki, Finland); Elja Herva (National Public Health Institute, Oulu, Finland); Anders Sjostedt (Umea University, Umea, Sweden); Anders Nystedt (Sunderby Hospital, Lulea, Sweden); and Anders Koch (Statens Serum Institut, Copenhagen, Denmark)

Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external